Fig. 2From: Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin GMarked weakness and CK elevation in CD59−/− rats following systemic AQP4-IgG administration. a AQP4-IgG pharmacokinetics in CD59+/+ and CD59−/− rats (mean ± S.E.M., 3 rats per genotype). b Clinical motor score at 24 h following IP injection of AQP4-IgG. Data shown for individual rats along with mean ± S.E.M. c Serum CK for indicated groups (mean ± S.E.M., 6 rats per genotype, except 4 rats for Compinh-treated group, **P < 0.01 comparing to AQP4-IgG-treated AQP4+/+ rats)Back to article page